Navigation Links
Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
Date:1/7/2008

mong existing oral OAB treatments, according to Dr. Sand. "Watson's oxybutynin gel is an elegant topical formulation that is clear, odorless and fast drying and will offer healthcare providers a unique treatment option for OAB patients," said Dr. Sand.

The Phase 3 multi-center, double blind, placebo-controlled study evaluated the efficacy and safety of OTG in 789 patients with overactive bladder. The primary objective of the study was to demonstrate that daily treatment of a 1g dose (approximately 1 mL) of OTG for 12 weeks was superior to placebo for the relief of OAB symptoms. Changes from baseline to endpoint were calculated from a three-day patient urinary diary and included a reduction in incontinence episodes and urinary frequency, and an increase in void volume. Additionally, 216 patients participated in a 14-week, open label, safety-extension study for a total of 26 weeks. During the double-blind portion of the trial, highly statistically significant improvements relative to placebo were seen on all of these endpoints.

Secondary endpoints also included a patient assessment of incontinence-specific, quality-of-life measures using multiple validated instruments including the Incontinence Impact Questionnaire (IIQ) and the King's Health Questionnaire, which indicated a significant positive effect of OTG treatment on quality-of-life total and subscale scores at endpoint in comparison with placebo.

OTG was well tolerated in the study. No serious adverse events related to the treatment were reported. Dry mouth (6.9%) and application site pruritis (2.1%) were the only treatment-related side effects reported at levels greater than 2%. Treatment-related adverse events that resulted in study discontinuation during the double-blind period were low (1.8%) and the similar for both the treatment and placebo groups.

Phase 1 studies have demonstrated that the steady-state plasma levels of oxybutynin show little fluctuation during the 24-hour dosin
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
5. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014   Bluegrass ... focused on innovating lifesaving devices and methods for ... million in Series A financing, which was led ... from the deal will allow Bluegrass Vascular to ... Catheter System, enhance manufacturing capabilities, and proceed with ...
(Date:7/30/2014)... 30, 2014  PDL BioPharma, Inc. (PDL) (NASDAQ: ... participate in the Jefferies 2014 Boston Healthcare Summit next ... will occur on August 6, 2014 and will not ... PDL BioPharma manages a portfolio of patents and ... antibody humanization patents and license agreements with various biotechnology ...
(Date:7/30/2014)... , 30. Juli 2014 Die ... führender Anbieter im Bereich Atemtherapie- und Druckzonenprodukte, ... Landgerichts München in Deutschland anfechten werden. Dieses ... Masken ein Patent von ResMed verletze. Apex ... wichtigen Ländern gegen verschiedene Patente von ResMed ...
Breaking Medicine Technology:Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3
... Near-Complete Mitigation of Choroidal,Neovascularization (CNV) in an AMD ... Lpath, Inc. ,the category leader in therapeutic agents ... standard animal,model of human age-related macular degeneration (AMD). ... meeting of the,Association of Research in Vision and ...
... of SEROQUEL XR--, WILMINGTON, Del., May 22, ... analyses from a large-scale,study that investigated the ... a once-daily medicine for the,treatment of schizophrenia ... annual meeting of the American Psychiatric Association,(APA). ...
Cached Medicine Technology:Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 2Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 3Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 4New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 2New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 3New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 4New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 5New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 6New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 7New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 8New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 9
(Date:7/30/2014)... (PRWEB) July 30, 2014 It is said ... proved this to be true as a product sponsor ... in Las Vegas this past June. , Lash Affair ... and overall success of the eyelash industry through collaboration so ... proud to have supported NEESA ’s event. Lash Affair’s ...
(Date:7/30/2014)... mutation linked to obesity respond differently to pictures of ... not have the genetic mutation, according to a new ... Clinical Endocrinology & Metabolism ( JCEM ). , ... results from a combination of eating too much, getting ... of appetizing foods that are high in calories can ...
(Date:7/30/2014)... Texas (PRWEB) July 30, 2014 The ... (2013-18)” provides an insight into the market dynamics and ... report covers the actual and forecasted market sizing of ... various factors fuelling the demand of the same. It ... segment and major players in the market. Further, the ...
(Date:7/30/2014)... July 30, 2014 Dialogic ... today announced that DollarPhone, the largest privately owned ... the Dialogic® ControlSwitch™ softswitch to offer ... number portability (LNP) to both its wholesale and ... ControlSwitch is able to power DollarPhone’s network infrastructure, ...
(Date:7/30/2014)... HealthDay Reporter , TUESDAY, July ... might set the stage for harmful health habits, including eating ... conducted from 1982 to 2012 also found a link between ... younger a woman was when she started her first diet, ... control behaviors -- like vomiting or laxative misuse," said study ...
Breaking Medicine News(10 mins):Health News:Lash Affair Launches a New Product as Sponsor of the First U.S. Lash Extension Competition 2Health News:Brain response to appetizing food cues varies among obese people 2Health News:Global Pulse Oximetry Market 2018 Opportunities and Trends Now Available at MarketReportsOnline.com 2Health News:Global Pulse Oximetry Market 2018 Opportunities and Trends Now Available at MarketReportsOnline.com 3Health News:DollarPhone Expands Prepaid and Wholesale Offerings With Enhanced Dialogic ControlSwitch 2Health News:DollarPhone Expands Prepaid and Wholesale Offerings With Enhanced Dialogic ControlSwitch 3Health News:Dieting at Young Age Often Backfires, Study Says 2Health News:Dieting at Young Age Often Backfires, Study Says 3
... analysis of records of pancreatic surgery during the last ... pancreatic cancer surgeon// Charles J. Yeo, M.D., Samuel D. ... College of Thomas Jefferson University and Thomas Jefferson University ... his colleagues have revealed that contrary to what many ...
... major intestinal surgery, including stomach reduction for obesity, may ... results of the study have been published in the ... findings on three patients with increasingly poor eyesight or ... the space of a year. None of the patients ...
... A number of Canadians are more obese ... smoking less, according to a new national health survey// . ... Canada, on Tuesday, revealed that there was an underestimation ... by approximately nine per cent. The survey also indicated ...
... that a man is very critical and is suspected to have ... in a Shenzhen hospital. It is very evident that the virus ... Health Protection said that the victim lives in Shenzhen and is ... residing in Shenzhen. He fell ill after he visited a wet ...
... Families who fear the transfer of genetic diseases to their progeny ... a major NHS bank of babies' stem cells//. ,Stem ... to treat diseases such as leukemia. However cord blood banking has ... public as well as clinicians, wherein blood is taken from the ...
... warn the number of New Zealanders who take party pills ... authorities argued taking// party pills escape people from taking drugs. ... used the pill atleast once – says researchers commissioned by ... physical and psychological parts such as sleeplessness, loss of appetite, ...
Cached Medicine News:Health News:Pancreatic Cancer Surgery Successful in 80-Year-Olds 2Health News:Pancreatic Cancer Surgery Successful in 80-Year-Olds 3Health News:Incidence Of Smoking Less, Obesity More, in Canada: StatsCan 2Health News:Bank of Stem Cells to Give Hope to Sick Children 2
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Nucleus manipulator used during phacoemulsification. Used to break-up the nuclues within the capsular bag during two-handed phaco techniques. Blunt round tip, angled 40 degrees, 11mm from tip. Tip an...
... effective upgrade path that allows users to ... modularity. The potential to combine two units ... a single stimulating coil. The ability to ... the power level of each Magstim 200 ...
... The Magstim Model 200 uses a ... otherwise inaccessible nerves. World market leader in ... developed by the University of Sheffield in ... cortical hemispheric and peripheral stimulation. Our best ...
Medicine Products: